Last reviewed · How we verify
NCT04526418
Evaluation of the 24/7 EEG SubQ System for Ultra Long-Term Recording of Patients With Epilepsy Involving the Temporal Lobe Region.
NA trial testing 24/7 EEG™ SubQ system in Epilepsy in 64 participants. Terminated before completion.
22 July 2025
Quick facts
| Lead sponsor | UNEEG Medical A/S |
|---|---|
| Phase | NA |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 64 |
| Start date | 21 April 2021 |
| Primary completion | 22 July 2025 |
| Estimated completion | 29 August 2025 |
| Sites | 12 locations across Belgium, United States, Germany |
Drugs / interventions tested
- 24/7 EEG™ SubQ system
Conditions studied
- Epilepsy — all drugs for Epilepsy →
Sponsor
UNEEG Medical A/S
Who can join
Adults 18 to 75, any sex, with Epilepsy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The 24/7 EEG™ SubQ system will be compared to simultaneously recorded video-EEG in the Epilepsy Monitoring Unit (gold standard) and to self-reported seizure log books throughout 12 weeks of outpatient EEG recording. The present study is a 12-week open-label, prospective study with a paired, comparative design for pivotal evaluation of the safety and effectiveness of the 24/7 EEGTM SubQ system in subjects with epilepsy involving the temporal lobe region . 2-5 sites in Europe Up to 10 sites in US
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04526418
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Epilepsy
Currently open trials in the same condition.
- NCT07095933 — The Safety and Efficacy Evaluation of Everolimus as an Adjunctive Treatment for Focal Refractory Epilepsy · EARLY_PHASE1 · recruiting
- NCT07224191 — Hippocampal Oscillations During Exploration · NA · recruiting
- NCT07219407 — A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures · Phase 2 · recruiting
- NCT07417280 — LIFUS For Neurological Disorders · NA · recruiting
- NCT07490769 — Levetiracetam Three Times Daily in Epilepsy · Phase 3 · recruiting
Other UNEEG Medical A/S trials
Trials by the same sponsor.
- NCT05495386 — Investigation of Hyposafe H02 Device in Patients With Type 1 Diabetes · NA · withdrawn
- NCT06934005 — Safety and Performance of Short- and Long-term Baseplates for Attaching the UNEEG Episight Recorder - Part II · NA · completed
- NCT05111847 — Safety and Performance of Short- and Long-term Baseplates for Attaching the UNEEG Episight Recorder - Part I · NA · completed
- NCT04513743 — Ultra Long-Term Sleep Monitoring Using UNEEG™ Medical 24/7 EEG™ SubQ · NA · completed
- NCT02925676 — Evaluation of the Hypoglycaemia Notification Device Hyposafe H02 · NA · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04526418 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by UNEEG Medical A/S
- Last refreshed: 5 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04526418.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing